{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"CDKN2B, a tumor suppressor and cell cycle regulator, is inactivated by mutation or deletion in various cancer types.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"11/16/2020",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "25873077",
        "23715670"
      ]
    },
    "description":"The CDKN2B D86N mutation is located in the cell cycle inhibitory region of the protein. This mutation has been found as a germline mutation in familial renal cell carcinoma (PMID: 25873077). Expression of this mutation in a renal cancer cell line demonstrated that it is inactivating as measured by decreased protein activity and increased colony formation compared to wildtype (PMID: 25873077, 23715670).",
    "knownEffect":"Loss-of-function"
  },
  "oncogenic":"Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"D86N",
    "alterationType":null,
    "consequence":"missense_variant",
    "entrezGeneId":1030,
    "hgvs":"9:g.22006148C>T",
    "hugoSymbol":"CDKN2B",
    "id":null,
    "proteinEnd":86,
    "proteinStart":86,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The CDKN2B D86N mutation is known to be oncogenic.",
  "vus":false
}